Monopar Therapeutics (MNPR) Preferred Shares (2016)

Monopar Therapeutics' (MNPR) quarterly Preferred Shares came in at $116.0 in Q4 2016.

Monopar Therapeutics (MNPR) Preferred Shares (2016) Analysis & Trends

Monopar Therapeutics has disclosed Preferred Shares across 1 years of filings, most recently posting $116.0 for Q4 2016.

Preferred Shares for Q4 2016 came in at $116.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $116.0 (changed N/A YoY), and the FY2016 annual result was $116.0, changed N/A from the prior year.
Preferred Shares came in at $116.0 for Q4 2016 at Monopar Therapeutics.
In the past five years, Preferred Shares ranged from a high of $116.0 in Q4 2016 to a low of $116.0 in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Monopar Therapeutics	441.25 Mn	441.25 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	116.00